Rocket Pharmaceuticals (RCKT) Assets Average (2015 - 2026)

Rocket Pharmaceuticals has reported Assets Average for 11 years, with the latest figure at $307.9 million in Q1 2026.

• Quarterly Assets Average fell 38.34% year-over-year to $307.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307.9 million (down 38.34% YoY) and the FY2025 annual result came in at $429.1 million, down 21.56% from the prior year.
• Assets Average fell to $307.9 million in Q1 2026 per RCKT's latest filing, from $349.2 million in the prior quarter.
• Over five years, Assets Average peaked at $532.9 million in Q1 2024 and troughed at $1.0 million in Q2 2022.
• A 5-year average of $278.1 million and a median of $307.9 million in 2026 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2026: Assets Average jumped 30820.33% in 2024, then tumbled 38.34% in 2026.
• Over 5 years, Assets Average stood at $276.8 million in 2022, then grew by 2.61% to $284.0 million in 2023, then jumped by 62.21% to $460.7 million in 2024, then dropped by 24.19% to $349.2 million in 2025, then dropped by 11.83% to $307.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $307.9 million, $349.2 million, and $394.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.